Biotech · Private company
Restem, LLC.
Track this companyFree. Adds Restem, LLC. to your Dealase workspace and tells you when its record changes.
Clinical trials42 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- ULSC (1.5 x 10^8 cells/dose)Phase 3 · Idiopathic Inflammatory Myositis (IIM)ClinicalTrials.gov · fetched Nov 12, 2026
- Umbilical Cord Lining Stem Cells (ULSC)Phase 2 · Covid19ClinicalTrials.gov · fetched Nov 12, 2026
- ULSCPhase 1 · FSHD - Facioscapulohumeral Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)PHASE2_PHASE3 · RECRUITING · started Jan 6, 2026ClinicalTrials.gov NCT07160205 · fetched Nov 12, 2026
- Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD)PHASE1 · RECRUITING · started Dec 1, 2025ClinicalTrials.gov NCT07086521 · fetched Nov 12, 2026
- Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM)EARLY_PHASE1 · COMPLETED · started Oct 6, 2021ClinicalTrials.gov NCT04723303 · fetched Nov 12, 2026
- Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDSPHASE1_PHASE2 · COMPLETED · started Dec 23, 2020ClinicalTrials.gov NCT04494386 · fetched Nov 12, 2026